Financial Times Asia Healthcare & Life Sciences Summit
Shaping the future of health care
Leading professionals and thought leaders will answer questions, propose solutions and discuss the future of the life sciences and health care industry throughout the Asia-Pacific region.
25 May 2016 | The Westin Singapore
Asia faces formidable health care challenges. An ageing population combined with longer life expectancy, as well as changing diets and lifestyles, are dramatically altering the region’s health profile. The surge in age-related health care requirements, and in the incidence of non-communicable diseases has put an additional burden on health care systems already struggling to cope. Governments have responded by increasing budgetary spending on health care infrastructure and services, and opening the door wider to private investment.
This has provided business opportunities for global and local health care and pharmaceuticals companies. But the huge health care market comes with challenges: poor distribution, lack of skilled personnel, pricing conundrums and constraining regulations, among others. Asia’s governments are adapting national health care policies to allow the private sector to share their health care load, but are mindful that they alone remain responsible for providing citizens with access to at least basic health care.
Visit the conference website at https://live.ft.com/Events/2017/FT-Asia-Healthcare-Life-Sciences-Summit to learn more about the speakers, agenda, and topics to be covered and to register. Please use marketing code DTTS2017 to receive 25% off the current registration rate.
Topics to be covered
- Making health care sustainable in Asia
- Intelligent technology = smarter health care
- Legal implications of health tech—reading the fine print
- Collaboration in pharma-health care—stronger together
- The business of health care
- Medical tourism—Asia’s other attraction
- Patient-centered health care: how workable is it in Asia?
- Health insurance: Who’s paying the bills?
- Rise of non-communicable diseases in Asia
- A closer look at diabetes in Asia
- Herve Gisserot, Head of Pharmaceuticals, Asia-Pacific, GlaxoSmithKline
- Bruce Liang, CEO, Integrated Health Information Systems; CIO, Ministry of Health, Singapore
- Rebecca George, Global Lead for Public Sector Health Care and Social Services, Deloitte
- Sajid Rahman, CEO, Telenor Health
- Jean Nehme, CEO and Co-founder, Touch Surgery
- Peter Fang, Head of Asia-Pacific, Shire
- Priya Matzen, Associate Director, Market Access and Public Affairs, South-east Asia, Novo Nordisk
- Rohan Hammett, Lead Clinical Partner, Deloitte Australia, Global Lead, Financial and Operational Improvement in Healthcare
- Cristina Parsons Perez, Capacity Development Director, NCD Alliance
- Allen Lai, Regional Managing Director, ACT Genomics Singapore
- Patrick Tan Boon Ooi, Deputy Executive Director, Biomedical Research Council, Agency for Science, Technology and Research, Singapore; Professor, Duke-NUS Medical School Singapore
- Yi Mien Koh, Group Medical Director, AIA
- How Ti Hwei, Country President, AstraZeneca Singapore; President, Singapore Association of Pharmaceutical Industries
- Zee Yoong Kang, CEO, Health Promotion Board, Singapore
- Srividya Jagannathan, Global Lead for Lifesciences, International Finance Corporation
- Joyce Chang, Director, Asia-Pacific, Joint Commission International
- Laxmikant Palo, Regional Director, Southeast Asia, Project HOPE
- Colin Albert, Commercial Head and Regional General Manager FMI, Roche Pharma APAC, Roche Singapore
- Isabel Torres, Global Head of Access to Medicines, Takeda Pharmaceuticals
- Roy Quek, Executive Chairman, Thomson Medical Group
- Maarten Kelder, Senior Vice-President, Strategy and Solutions, Zuellig Pharma
- Ramesh Kumar, Head APAC Sub-Region, Ascensia Diabetes Care
- Ramesh Rajentheran, Group Chief Financial Officer, Fullerton Health